Potent & Selective TKI Shows Potential With RET-Altered Cancer Patients
Preliminary proof-of-concept data were presented from an ongoing phase I clinical trial evaluating the use of the next-generation, RET tyrosine kinase inhibitor BLU-667 at the AACR 2018 Annual Meeting.
Read More